Stock search

Ticker or company name

Moderna

MRNA · NASDAQ · Biotechnology

$215,27Down −8,10 (−3,63%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$86,5 bn
Div. yield
—
Year to date
+657,4%
52 weeks: $22,28$280,80

Ratio score

22/100
Ratio would not consider buying

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

2 ✓ · 0 — · 7 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTMn/a—42,1
Forward P/En/a—18,7
PEGn/a—4,1
P/S35,84,76,6
EV/EBITDA105,9—28,2
P/FCF101,4—26,0
P/B13,22,89,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 31 analysts

Buy
10
Hold
17
Sell
4

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 2026−1,280,38Up +129,8%
Q2 2026−2,12−1,97Up +7,3%
Q1 2026−4,04−3,40Up +15,8%
Q4 2025−2,70−2,11Up +21,7%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue1,31 bn145 m389 m678 m1,02 bn142 m108 m966 m1,86 bn241 m167 m2,81 bn
EPS0,38−1,97−3,40−2,11−0,51−2,13−2,52−2,910,03−3,33−3,070,56
Margin12,3%−539,3%−345,2%−121,8%−19,7%−581,0%−899,1%−115,9%0,7%−530,7%−703,6%7,7%
FCF−1,61 bn−563 m−692 m891 m−880 m−922 m−1,15 bn303 m−1,72 bn−1,46 bn−1,19 bn402 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $78,9 m.

NameAmountSharesPrice
hoge stephen15 Oct 2026 · sale$8,64 m39 145$220,72
hoge stephen14 Oct 2026 · sale$96 368450$214,15
hoge stephen14 Oct 2026 · sale$8,28 m38 774$213,47
hoge stephen15 Sep 2026 · sale$5,88 m40 281$146,07
hoge stephen14 Sep 2026 · sale$5,81 m40 294$144,13
mock james m10 Sep 2026 · sale$2,02 m15 000$134,49
mock james m10 Sep 2026 · sale$2,67 m19 836$134,49
klinger shannon thyme1 Sep 2026 · sale$485 7663 471$139,95
bancel stephane5 Aug 2026 · sale$11,0 m187 044$58,79
bancel stephane5 Aug 2026 · sale$2,32 m39 891$58,12
bancel stephane5 Aug 2026 · sale$7,11 m124 838$56,96
bancel stephane5 Aug 2026 · sale$8,29 m147 473$56,21
hoge stephen15 Jul 2026 · sale$3,61 m53 336$67,60
klinger shannon thyme4 Jun 2026 · sale$173 5503 471$50,00
afeyan noubar21 May 2026 · sale$433 8799 263$46,84

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
7 Dec 2018

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
BIIBBiogen$251,6531would not consider107,8+2,3%3,4%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
AMGNAmgen$462,3267would watch26,8+8,2%24,1%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.